H3C7
gene geneOn this page
Also known as H3/i
Summary
H3C7 (H3 clustered histone 7, HGNC:4773) is a protein-coding gene on chromosome 6p22.2, encoding Histone H3.1 (P68431). Core component of nucleosome.
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. This structure consists of approximately 146 bp of DNA wrapped around a nucleosome, an octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H3 family. Transcripts from this gene lack polyA tails; instead, they contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6p22-p21.3.
Source: NCBI Gene 8968 — RefSeq curated summary.
At a glance
- GWAS associations: 15
- Clinical variants (ClinVar): 5 total
- MANE Select transcript:
NM_021018
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4773 |
| Approved symbol | H3C7 |
| Name | H3 clustered histone 7 |
| Location | 6p22.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H3/i |
| Ensembl gene | ENSG00000277775 |
| Ensembl biotype | protein_coding |
| OMIM | 602816 |
| Entrez | 8968 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000618052
RefSeq mRNA: 1 — MANE Select: NM_021018
NM_021018
CCDS: CCDS4600
Canonical transcript exons
ENST00000618052 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003721828 | 26250142 | 26250635 |
Expression profiles
Bgee: expression breadth broad, 84 present calls, max score 92.20.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 516.2768 / max 7959.0578, expressed in 1679 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 72338 | 515.2403 | 1679 |
| 72337 | 1.0366 | 494 |
Top tissues by expression
246 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| adrenal tissue | UBERON:0018303 | 92.20 | gold quality |
| bone marrow cell | CL:0002092 | 85.67 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.84 | gold quality |
| colonic epithelium | UBERON:0000397 | 72.23 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 61.18 | gold quality |
| bone marrow | UBERON:0002371 | 59.27 | gold quality |
| tonsil | UBERON:0002372 | 59.23 | gold quality |
| stromal cell of endometrium | CL:0002255 | 55.47 | gold quality |
| ventricular zone | UBERON:0003053 | 54.94 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 49.33 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 49.30 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 49.20 | gold quality |
| hair follicle | UBERON:0002073 | 49.18 | gold quality |
| ganglionic eminence | UBERON:0004023 | 49.18 | gold quality |
| olfactory bulb | UBERON:0002264 | 48.92 | gold quality |
| myocardium | UBERON:0002349 | 48.87 | gold quality |
| quadriceps femoris | UBERON:0001377 | 48.85 | gold quality |
| type B pancreatic cell | CL:0000169 | 48.83 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 48.55 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 48.50 | gold quality |
| vastus lateralis | UBERON:0001379 | 48.25 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 48.24 | gold quality |
| embryo | UBERON:0000922 | 48.21 | gold quality |
| orbitofrontal cortex | UBERON:0004167 | 48.20 | gold quality |
| deltoid | UBERON:0001476 | 48.18 | gold quality |
| upper arm skin | UBERON:0004263 | 48.06 | gold quality |
| cervix epithelium | UBERON:0004801 | 48.04 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 48.00 | gold quality |
| oviduct epithelium | UBERON:0004804 | 48.00 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 47.92 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.29 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 2)
- CREB controls MSK1-mediated phosphorylation of histone H3 at the c-fos promoter in vitro (PMID:20089855)
- These results uncover a novel role of CENP-F in regulation of epigenetic modification on histone H3. (PMID:20213041)
Cross-species orthologs
24 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zgc:173552 | ENSDARG00000051737 |
| danio_rerio | si:ch1073-153i20.2 | ENSDARG00000105345 |
| danio_rerio | zgc:173552 | ENSDARG00000110909 |
| danio_rerio | si:ch211-113a14.27 | ENSDARG00000111396 |
| danio_rerio | si:ch211-113a14.20 | ENSDARG00000112131 |
| danio_rerio | zgc:173552 | ENSDARG00000112175 |
| danio_rerio | si:ch211-113a14.23 | ENSDARG00000114334 |
| rattus_norvegicus | Hist1h2ail1 | ENSRNOG00000064755 |
| drosophila_melanogaster | His3:CG33812 | FBGN0053812 |
| caenorhabditis_elegans | WBGENE00001876 | |
| caenorhabditis_elegans | WBGENE00001880 | |
| caenorhabditis_elegans | WBGENE00001883 | |
| caenorhabditis_elegans | WBGENE00001887 | |
| caenorhabditis_elegans | WBGENE00001891 | |
| caenorhabditis_elegans | WBGENE00001899 | |
| caenorhabditis_elegans | WBGENE00001901 | |
| caenorhabditis_elegans | WBGENE00001906 | |
| caenorhabditis_elegans | WBGENE00001914 | |
| caenorhabditis_elegans | WBGENE00001916 | |
| caenorhabditis_elegans | WBGENE00001919 | |
| caenorhabditis_elegans | WBGENE00001923 | |
| caenorhabditis_elegans | WBGENE00001929 | |
| caenorhabditis_elegans | WBGENE00001933 | |
| caenorhabditis_elegans | WBGENE00001937 |
Paralogs (20): CENPA (ENSG00000115163), H3-3B (ENSG00000132475), H3-3A (ENSG00000163041), H3-4 (ENSG00000168148), H3C13 (ENSG00000183598), H3-5 (ENSG00000188375), H3C12 (ENSG00000197153), H3C4 (ENSG00000197409), H3C14 (ENSG00000203811), H3C15 (ENSG00000203852), H3Y2 (ENSG00000268799), H3Y1 (ENSG00000269466), H3-7 (ENSG00000273213), H3C8 (ENSG00000273983), H3C6 (ENSG00000274750), H3C11 (ENSG00000275379), H3C1 (ENSG00000275714), H3C10 (ENSG00000278828), H3C2 (ENSG00000286522), H3C3 (ENSG00000287080)
Protein
Protein identifiers
Histone H3.1 — P68431 (reviewed: P68431)
Alternative names: Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/i, Histone H3/j, Histone H3/k, Histone H3/l
All UniProt accessions (1): P68431
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA. Interacts with TONSL; CHAF1A; CHAF1B; MCM2 and DNAJC9. Interacts with NASP; NASP is a histone chaperone that stabilizes and maintains a soluble pool of Histone H3-H4 dimers.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Acetylation is generally linked to gene activation. Acetylation on Lys-10 (H3K9ac) impairs methylation at Arg-9 (H3R8me2s). Acetylation on Lys-19 (H3K18ac) and Lys-24 (H3K24ac) favors methylation at Arg-18 (H3R17me). Acetylation at Lys-123 (H3K122ac) by EP300/p300 plays a central role in chromatin structure: localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Citrullination at Arg-9 (H3R8ci) and/or Arg-18 (H3R17ci) by PADI4 impairs methylation and represses transcription. Asymmetric dimethylation at Arg-18 (H3R17me2a) by CARM1 is linked to gene activation. Symmetric dimethylation at Arg-9 (H3R8me2s) by PRMT5 is linked to gene repression. Asymmetric dimethylation at Arg-3 (H3R2me2a) by PRMT6 is linked to gene repression and is mutually exclusive with H3 Lys-5 methylation (H3K4me2 and H3K4me3). H3R2me2a is present at the 3’ of genes regardless of their transcription state and is enriched on inactive promoters, while it is absent on active promoters. Methylation at Lys-5 (H3K4me), Lys-37 (H3K36me) and Lys-80 (H3K79me) are linked to gene activation. Methylation at Lys-5 (H3K4me) facilitates subsequent acetylation of H3 and H4. Methylation at Lys-80 (H3K79me) is associated with DNA double-strand break (DSB) responses and is a specific target for TP53BP1. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are linked to gene repression. Methylation at Lys-10 (H3K9me) is a specific target for HP1 proteins (CBX1, CBX3 and CBX5) and prevents subsequent phosphorylation at Ser-11 (H3S10ph) and acetylation of H3 and H4. Methylation at Lys-5 (H3K4me) and Lys-80 (H3K79me) require preliminary monoubiquitination of H2B at ‘Lys-120’. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are enriched in inactive X chromosome chromatin. Monomethylation at Lys-57 (H3K56me1) by EHMT2/G9A in G1 phase promotes interaction with PCNA and is required for DNA replication. Phosphorylated at Thr-4 (H3T3ph) by VRK1. Phosphorylated at Thr-4 (H3T3ph) by HASPIN during prophase and dephosphorylated during anaphase. Phosphorylation at Ser-11 (H3S10ph) by AURKB is crucial for chromosome condensation and cell-cycle progression during mitosis and meiosis. In addition phosphorylation at Ser-11 (H3S10ph) by RPS6KA4 and RPS6KA5 is important during interphase because it enables the transcription of genes following external stimulation, like mitogens, stress, growth factors or UV irradiation and result in the activation of genes, such as c-fos and c-jun. Phosphorylation at Ser-11 (H3S10ph), which is linked to gene activation, prevents methylation at Lys-10 (H3K9me) but facilitates acetylation of H3 and H4. Phosphorylation at Ser-11 (H3S10ph) by AURKB mediates the dissociation of HP1 proteins (CBX1, CBX3 and CBX5) from heterochromatin. Phosphorylation at Ser-11 (H3S10ph) is also an essential regulatory mechanism for neoplastic cell transformation. Phosphorylated at Ser-29 (H3S28ph) by MAP3K20 isoform 1, RPS6KA5 or AURKB during mitosis or upon ultraviolet B irradiation. Phosphorylation at Thr-7 (H3T6ph) by PRKCB is a specific tag for epigenetic transcriptional activation that prevents demethylation of Lys-5 (H3K4me) by LSD1/KDM1A. At centromeres, specifically phosphorylated at Thr-12 (H3T11ph) from prophase to early anaphase, by DAPK3 and PKN1. Phosphorylation at Thr-12 (H3T11ph) by PKN1 or isoform M2 of PKM (PKM2) is a specific tag for epigenetic transcriptional activation that promotes demethylation of Lys-10 (H3K9me) by KDM4C/JMJD2C. Phosphorylation at Thr-12 (H3T11ph) by chromatin-associated CHEK1 regulates the transcription of cell cycle regulatory genes by modulating acetylation of Lys-10 (H3K9ac). Phosphorylation at Tyr-42 (H3Y41ph) by JAK2 promotes exclusion of CBX5 (HP1 alpha) from chromatin. Monoubiquitinated at Lys-15 (H3K14ub), Lys-19 (H3K18ub) and Lys-24 (H3K23ub) by UHRF1 and HLTF at hemimethylated DNA sites following DNA replication, promoting recruitment of DNMT1 DNA methyltransferase and replication-coupled DNA methylation maintenance. Monoubiquitinated by RAG1 in lymphoid cells, monoubiquitination is required for V(D)J recombination. Ubiquitinated by the CUL4-DDB-RBX1 complex in response to ultraviolet irradiation. This may weaken the interaction between histones and DNA and facilitate DNA accessibility to repair proteins. Lysine deamination at Lys-5 (H3K4all) to form allysine is mediated by LOXL2. Allysine formation by LOXL2 only takes place on H3K4me3 and results in gene repression. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Butyrylation of histones marks active promoters and competes with histone acetylation. It is present during late spermatogenesis. Succinylation at Lys-80 (H3K79succ) by KAT2A takes place with a maximum frequency around the transcription start sites of genes. It gives a specific tag for epigenetic transcription activation. Desuccinylation at Lys-123 (H3K122succ) by SIRT7 in response to DNA damage promotes chromatin condensation and double-strand breaks (DSBs) repair. Serine ADP-ribosylation by PARP1 or PARP2 constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Serine ADP-ribosylation at Ser-11 (H3S10ADPr) promotes recruitment of CHD1L. H3S10ADPr is mutually exclusive with phosphorylation at Ser-11 (H3S10ph) and impairs acetylation at Lys-10 (H3K9ac). Serotonylated by TGM2 at Gln-6 (H3Q5ser) during serotonergic neuron differentiation. H3Q5ser is associated with trimethylation of Lys-5 (H3K4me3) and enhances general transcription factor IID (TFIID) complex-binding to H3K4me3, thereby facilitating transcription. Dopaminylated by TGM2 at Gln-6 (H3Q5dop) in ventral tegmental area (VTA) neurons. H3Q5dop mediates neurotransmission-independent role of nuclear dopamine by regulating relapse-related transcriptional plasticity in the reward system. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Disease relevance. Glioma (GLM) [MIM:137800] Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. The gene represented in this entry is involved in disease pathogenesis. HIST1H3B mutations affecting residue Lys-28 involved in post-translational modifications of histone H3.1 are recurrent in malignant, aggressive gliomas including pediatric non-brain stem glioblastoma and diffuse intrinsic pontine glioma (DIPG). The mechanism through which mutations lead to tumorigenesis involves altered histone methylation, impaired regulation of Polycomb repressive complex 2 (PRC2) activity, and aberrant epigenetic regulation of gene expression. HIST1H3B or HIST1H3C mutations affecting residue Lys-37 of histone H3.1 are involved in the pathogenesis of pediatric undifferentiated soft tissue sarcomas. The mechanism through which mutations lead to tumorigenesis involves altered histones methylation with gain of global H3K27 methylation, altered Polycomb repressive complex 1 (PRC1) activity, aberrant epigenetic regulation of gene expression and impaired differentiation of mesenchimal progenitor cells.
Miscellaneous. This histone is only present in mammals and is enriched in acetylation of Lys-15 and dimethylation of Lys-10 (H3K9me2).
Similarity. Belongs to the histone H3 family.
RefSeq proteins (1): NP_066298* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000164 | Histone_H3/CENP-A | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
Pfam: PF00125
UniProt features (146 total): modified residue 120, strand 8, sequence conflict 4, helix 4, cross-link 3, sequence variant 3, initiator methionine 1, chain 1, lipid moiety-binding region 1, region of interest 1
Structure
Experimental structures (PDB)
548 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 5SVY | X-RAY DIFFRACTION | 1.05 |
| 2V89 | X-RAY DIFFRACTION | 1.1 |
| 5SZC | X-RAY DIFFRACTION | 1.19 |
| 5SZB | X-RAY DIFFRACTION | 1.2 |
| 6BHD | X-RAY DIFFRACTION | 1.25 |
| 4UP0 | X-RAY DIFFRACTION | 1.28 |
| 5WXH | X-RAY DIFFRACTION | 1.3 |
| 5FFV | X-RAY DIFFRACTION | 1.3 |
| 4L7X | X-RAY DIFFRACTION | 1.35 |
| 6BHE | X-RAY DIFFRACTION | 1.35 |
| 6BHI | X-RAY DIFFRACTION | 1.4 |
| 3ASL | X-RAY DIFFRACTION | 1.41 |
| 5TDR | X-RAY DIFFRACTION | 1.42 |
| 2RI7 | X-RAY DIFFRACTION | 1.45 |
| 4X3K | X-RAY DIFFRACTION | 1.45 |
| 6BHG | X-RAY DIFFRACTION | 1.45 |
| 5GH9 | X-RAY DIFFRACTION | 1.45 |
| 3V43 | X-RAY DIFFRACTION | 1.47 |
| 5JIY | X-RAY DIFFRACTION | 1.48 |
| 8IJ0 | X-RAY DIFFRACTION | 1.52 |
| 3RIY | X-RAY DIFFRACTION | 1.55 |
| 5SVX | X-RAY DIFFRACTION | 1.56 |
| 2VPG | X-RAY DIFFRACTION | 1.6 |
| 4LK9 | X-RAY DIFFRACTION | 1.6 |
| 4Y6L | X-RAY DIFFRACTION | 1.6 |
| 5T1I | X-RAY DIFFRACTION | 1.6 |
| 5U2J | X-RAY DIFFRACTION | 1.6 |
| 7CFP | X-RAY DIFFRACTION | 1.6 |
| 7CFQ | X-RAY DIFFRACTION | 1.6 |
| 6V41 | X-RAY DIFFRACTION | 1.6 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P68431-F1 | 86.95 | 0.71 |
Antibody-complex structures (SAbDab): 19 — 4YHP, 4YHZ, 7K5X, 7K5Y, 7K60, 7K61, 7K63, 7U0G, 7U0I, 7U0J, 8DK5, 8EVG, 8EVH, 8EVI, 8EVJ, 8SPS, 8SPU, 8SYP, 8VFX
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (124): 5, 80, 80, 80, 80, 80, 80, 80, 80, 80, 80, 5, 81, 87, 108, 116, 116, 123, 123, 123 …
Function
Pathways and Gene Ontology
Reactome pathways
48 pathways
| ID | Pathway |
|---|---|
| R-HSA-1266695 | Interleukin-7 signaling |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214841 | PKMTs methylate histone lysines |
| R-HSA-3214842 | HDMs demethylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-3214858 | RMTs methylate histone arginines |
| R-HSA-3247509 | Chromatin modifying enzymes |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-73728 | RNA Polymerase I Promoter Opening |
| R-HSA-73772 | RNA Polymerase I Promoter Escape |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs |
| R-HSA-9018519 | Estrogen-dependent gene expression |
| R-HSA-912446 | Meiotic recombination |
| R-HSA-9609690 | HCMV Early Events |
| R-HSA-9610379 | HCMV Late Events |
MSigDB gene sets: 198 (showing top):
REACTOME_MEIOTIC_RECOMBINATION, GOBP_CHROMOSOME_ORGANIZATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_TELOMERE_ORGANIZATION, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, FISCHER_DREAM_TARGETS, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_CHROMATIN_REMODELING, GOBP_HETEROCHROMATIN_ORGANIZATION, TTTNNANAGCYR_UNKNOWN, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION
GO Biological Process (5): chromatin organization (GO:0006325), nucleosome assembly (GO:0006334), telomere organization (GO:0032200), epigenetic regulation of gene expression (GO:0040029), gene expression (GO:0010467)
GO Molecular Function (5): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), cadherin binding (GO:0045296), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)
GO Cellular Component (8): nucleosome (GO:0000786), extracellular region (GO:0005576), nucleus (GO:0005634), nucleoplasm (GO:0005654), membrane (GO:0016020), protein-containing complex (GO:0032991), extracellular exosome (GO:0070062), chromosome (GO:0005694)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Chromatin modifying enzymes | 5 |
| Epigenetic regulation of gene expression | 2 |
| Cellular Senescence | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Signaling by Interleukins | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Mitotic Prophase | 1 |
| Chromatin organization | 1 |
| Gene Silencing by RNA | 1 |
| Activation of HOX genes during differentiation | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| chromatin | 2 |
| cellular component organization | 1 |
| chromatin organization | 1 |
| nucleosome organization | 1 |
| protein-DNA complex assembly | 1 |
| chromosome organization | 1 |
| chromatin remodeling | 1 |
| regulation of gene expression | 1 |
| macromolecule biosynthetic process | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| cell adhesion molecule binding | 1 |
| protein dimerization activity | 1 |
| binding | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cellular_component | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
0 interactions, top by confidence (×1000):
IntAct
448 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| H3C1 | CHAF1A | psi-mi:“MI:0914”(association) | 0.910 |
| NASP | H3C1 | psi-mi:“MI:0915”(physical association) | 0.910 |
| SUZ12 | EED | psi-mi:“MI:0914”(association) | 0.910 |
| H3C1 | H4C16 | psi-mi:“MI:0915”(physical association) | 0.890 |
| H4C16 | H3C1 | psi-mi:“MI:0407”(direct interaction) | 0.890 |
| H2AC4 | H2BC11 | psi-mi:“MI:0915”(physical association) | 0.850 |
| H3C1 | RBBP4 | psi-mi:“MI:0914”(association) | 0.840 |
| H3C1 | DNAJC9 | psi-mi:“MI:0915”(physical association) | 0.810 |
| NASP | H3C1 | psi-mi:“MI:0915”(physical association) | 0.780 |
| H3C1 | NASP | psi-mi:“MI:0915”(physical association) | 0.780 |
| H3C1 | HAT1 | psi-mi:“MI:0914”(association) | 0.770 |
| H2AZ1 | ZNHIT1 | psi-mi:“MI:0914”(association) | 0.770 |
| H3C1 | MCM2 | psi-mi:“MI:0915”(physical association) | 0.710 |
| H3C1 | MCM2 | psi-mi:“MI:0914”(association) | 0.710 |
| KDM1A | psi-mi:“MI:0915”(physical association) | 0.700 | |
| HTT | H3C1 | psi-mi:“MI:0915”(physical association) | 0.700 |
BioGRID (3102): HIST1H3A (Affinity Capture-Western), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3H (Two-hybrid), FBLIM1 (Two-hybrid), HIST1H3A (Reconstituted Complex), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), KAT2B (Co-localization), HIST1H3A (Biochemical Activity)
ESM2 similar proteins: A1CP80, A1D240, A2QRR5, A3LXD5, A4RCX7, A5DFC5, A5DG57, P02299, P07041, P08898, P09988, P0CO04, P0CO05, P10651, P23753, P61832, P61834, P61835, P68431, P68432, P68433, P84227, P84228, P84229, P84230, P84231, P84233, P84234, P84235, P84236, P84237, P84238, P84239, Q0D0E8, Q0UY45, Q1E225, Q28D37, Q2UCQ0, Q4IER8, Q4QRF4
Diamond homologs: A1CP80, A1D240, A2QRR5, A2Y533, A3GHN6, A3LXD5, A4RCX7, A5DFC5, A5DG57, A5DWE2, A5E094, C0HL66, C0HL67, P02299, P02301, P07041, P08903, P09988, P0CO04, P0CO05, P10651, P23753, P59226, P61830, P61831, P61832, P61833, P61834, P61835, P61836, P68427, P68428, P68429, P68430, P68431, P68432, P68433, P69071, P69072, P69073
SIGNOR signaling
75 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| AURKB | “down-regulates activity” | H3C1 | phosphorylation |
| AURKB | “up-regulates activity” | H3C1 | phosphorylation |
| AURKC | “up-regulates activity” | H3C1 | phosphorylation |
| RPS6KA3 | “down-regulates activity” | H3C1 | phosphorylation |
| RPS6KA5 | “down-regulates activity” | H3C1 | phosphorylation |
| TGM2 | unknown | H3C1 | phosphorylation |
| PBK | unknown | H3C1 | phosphorylation |
| MAML1 | “down-regulates activity” | H3C1 | acetylation |
| PIM1 | “down-regulates activity” | H3C1 | phosphorylation |
| VRK1 | unknown | H3C1 | phosphorylation |
| MAPK14 | unknown | H3C1 | phosphorylation |
| PRKCD | “up-regulates activity” | H3C1 | phosphorylation |
| PIM | “down-regulates activity” | H3C1 | phosphorylation |
| KDM6A | “down-regulates activity” | H3C1 | demethylation |
| KDM6B | “down-regulates activity” | H3C1 | demethylation |
| CTNNB1 | “up-regulates activity” | H3C1 | |
| “Polycomb repressive complex 2” | “up-regulates activity” | H3C1 | methylation |
| KDM4B | “down-regulates activity” | H3C1 | demethylation |
| KDM4C | “down-regulates activity” | H3C1 | demethylation |
| SETDB2 | “up-regulates activity” | H3C1 | methylation |
| KDM5A | “up-regulates activity” | H3C1 | demethylation |
| KDM5B | “up-regulates activity” | H3C1 | demethylation |
| KDM5C | “up-regulates activity” | H3C1 | demethylation |
| KDM5D | “up-regulates activity” | H3C1 | demethylation |
| “Set1-Ash2 HMT complex” | “down-regulates activity” | H3C1 | methylation |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Regulation of PTEN gene transcription | 9 | 19.4× | 4e-08 |
| Defective pyroptosis | 10 | 18.9× | 1e-08 |
| Negative Regulation of CDH1 Gene Transcription | 13 | 18.8× | 7e-11 |
| PRC2 methylates histones and DNA | 10 | 18.4× | 1e-08 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 10 | 18.4× | 1e-08 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 5 | 18.1× | 8e-05 |
| ChAHP complex assembly | 8 | 17.8× | 4e-07 |
| Transcriptional Regulation by E2F6 | 5 | 17.6× | 9e-05 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| heterochromatin formation | 10 | 24.6× | 3e-09 |
| nucleosome assembly | 17 | 23.0× | 8e-16 |
| chromatin organization | 12 | 11.4× | 1e-07 |
| chromatin remodeling | 15 | 10.5× | 3e-09 |
| DNA replication | 6 | 9.5× | 5e-03 |
| DNA repair | 13 | 8.0× | 2e-06 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
5 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 5 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
119 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:26250391:A:AC | donor_gain | 0.7500 |
| 6:26250392:C:CC | donor_gain | 0.7500 |
| 6:26250579:A:AC | donor_gain | 0.7500 |
| 6:26250580:C:CC | donor_gain | 0.7500 |
| 6:26250389:GTA:G | donor_loss | 0.7400 |
| 6:26250390:TACCA:T | donor_loss | 0.7400 |
| 6:26250391:ACCA:A | donor_loss | 0.7400 |
| 6:26250392:C:G | donor_loss | 0.7400 |
| 6:26250387:ACGT:A | donor_loss | 0.7300 |
| 6:26250425:G:C | donor_gain | 0.7100 |
| 6:26250580:CGAG:C | donor_gain | 0.7100 |
| 6:26250197:ATGC:A | donor_gain | 0.6900 |
| 6:26250392:CCAGA:C | donor_gain | 0.6600 |
| 6:26250386:CACG:C | donor_loss | 0.6400 |
| 6:26250322:T:TA | donor_gain | 0.5800 |
| 6:26250410:G:C | donor_gain | 0.5800 |
| 6:26250467:CA:C | donor_gain | 0.5700 |
| 6:26250383:T:TA | donor_gain | 0.5600 |
| 6:26250468:A:AC | donor_gain | 0.5600 |
| 6:26250397:CG:C | acceptor_gain | 0.5500 |
| 6:26250474:A:T | donor_gain | 0.5500 |
| 6:26250580:CGA:C | donor_gain | 0.5300 |
| 6:26250207:T:A | donor_gain | 0.5000 |
| 6:26250385:TCAC:T | donor_loss | 0.4900 |
| 6:26250197:ATG:A | donor_gain | 0.4800 |
| 6:26250250:G:C | donor_gain | 0.4600 |
| 6:26250334:A:AC | donor_gain | 0.4400 |
| 6:26250308:AAG:A | donor_gain | 0.4300 |
| 6:26250392:CCAG:C | donor_gain | 0.4200 |
| 6:26250411:C:A | acceptor_gain | 0.4200 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000465845 (6:26249769 C>T), RS1000601191 (6:26249935 A>G), RS1001532143 (6:26250701 A>T), RS1001720064 (6:26252297 C>T), RS1005553179 (6:26252320 G>A), RS1005648710 (6:26252540 G>A,C), RS1007473620 (6:26250747 T>A,G), RS1007855176 (6:26249862 T>C), RS1008594290 (6:26252556 T>C), RS1009216667 (6:26249836 C>A,T), RS1009493625 (6:26251659 T>A,C), RS1010222020 (6:26251129 G>A), RS1010505403 (6:26250890 G>A), RS1012406026 (6:26249754 C>A,G,T), RS1012467845 (6:26252624 G>A,C)
Disease associations
OMIM: gene MIM:602816 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
15 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004521_113 | Autism spectrum disorder or schizophrenia | 3.000000e-19 |
| GCST004521_142 | Autism spectrum disorder or schizophrenia | 2.000000e-09 |
| GCST004521_169 | Autism spectrum disorder or schizophrenia | 4.000000e-14 |
| GCST004521_69 | Autism spectrum disorder or schizophrenia | 8.000000e-24 |
| GCST004521_83 | Autism spectrum disorder or schizophrenia | 1.000000e-13 |
| GCST004571_19 | Iron status biomarkers (total iron binding capacity) | 2.000000e-08 |
| GCST004572_27 | Iron status biomarkers (transferrin saturation) | 2.000000e-08 |
| GCST007294_143 | Body fat distribution (trunk fat ratio) | 5.000000e-29 |
| GCST007294_82 | Body fat distribution (trunk fat ratio) | 1.000000e-48 |
| GCST007295_120 | Body fat distribution (leg fat ratio) | 2.000000e-46 |
| GCST007295_91 | Body fat distribution (leg fat ratio) | 1.000000e-26 |
| GCST010141_1 | Beef consumption | 7.000000e-13 |
| GCST010143_19 | Meat-related diet | 5.000000e-13 |
| GCST010143_31 | Meat-related diet | 7.000000e-09 |
| GCST010143_5 | Meat-related diet | 4.000000e-09 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006334 | total iron binding capacity |
| EFO:0004341 | body fat distribution |
| EFO:0008111 | diet measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
Binding affinities (BindingDB)
3 measured of 6 human assays (6 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value | Patent |
|---|---|---|---|
| N-hydroxy-3-(2-phenethyl-1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide | EC50 | 500 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
| 3-(1-(3-(dimethylamino)-2,2-dimethylpropyl)-2-phenethyl-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide | EC50 | 1100 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
| N-hydroxy-3-(2-phenethyl-1-(3,4,5-trimethoxybenzyl)-1H-benzo[d]imidazol-5-yl)acrylamide | EC50 | 1700 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
CTD chemical–gene interactions
33 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, affects cotreatment, increases expression | 2 |
| Doxorubicin | decreases expression, increases expression | 2 |
| Silicon Dioxide | decreases expression, increases expression | 2 |
| Particulate Matter | increases abundance, increases expression, decreases expression | 2 |
| afuresertib | decreases expression | 1 |
| propionaldehyde | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | decreases expression | 1 |
| thallium sulfate | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| 2-bromopalmitate | decreases reaction, increases abundance, increases palmitoylation | 1 |
| versicolorin A | decreases expression | 1 |
| picene | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| incobotulinumtoxinA | decreases expression | 1 |
| MT19c compound | decreases expression | 1 |
| Air Pollutants | increases expression, increases abundance | 1 |
| Aminoglutethimide | increases expression | 1 |
| Benzo(a)pyrene | increases expression | 1 |
| Berberine | decreases expression | 1 |
| Cadmium | increases abundance, increases palmitoylation, decreases reaction | 1 |
| Demecolcine | decreases expression | 1 |
| Dexamethasone | increases expression, affects cotreatment | 1 |
| Indomethacin | affects cotreatment, increases expression | 1 |
| Lucanthone | decreases expression | 1 |
| Tetrachlorodibenzodioxin | affects expression | 1 |
| Thiram | increases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Urethane | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.